Friday, September 29, 2023


Biotechnology News Magazine

Review in Chinese Medical Journal Explores Effect of Gut Microbiota on Inflammatory Bowel Disease

Researchers review advances in the characterization and treatment of imbalances in gut microbiota in inflammatory bowel disease

Latest Posts

Airway Therapeutics Completes Dose Escalation in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia

Airway Therapeutics began recruiting patients on March 28, 2023, for daily treatment up to 7 days at the highest dose of zelpultide alfa (rhSP-D) following a Data Safety Monitoring Committee (DSMC) report of no safety concerns.

Roche introduces navify® Algorithm Suite, a digital library of medical algorithms that enhances clinical decision-making to optimise patient care

At the global HIMSS1 Conference, Roche showcases navify Algorithm Suite, a single platform offering clinicians access to medical algorithms generating insights to help improve care decisions.

PathO3Gen Solutions UVZone® Proven 99.9993% Effective Against Candida Auris: Shoes and Floors in Healthcare Facilities Should Be Addressed as Outbreak Continues

PathO3Gen Solutions’ multi-patented UVZone Shoe Sanitizing Stations, when placed in high-traffic and high-risk areas, enhance healthcare facility infection control measures, and may improve overall hospital biosafety.

Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.

Under the terms of Pharming's 2019 exclusive license agreement with Novartis for leniolisib, the corresponding first commercial sale of Joenja® triggers a $10 million milestone payment by Pharming to Novartis.

The human gut is inhabited by a plethora of micro-organisms, collectively called the “microbiota,” which are important for normal physiological processes. “Dysbiosis” or an imbalance in their populations can, however, contribute to the pathology of gastrointestinal diseases such as inflammatory bowel disease (IBD).

IBD, a disease highly prone to relapse, is known to be an outcome of genetic factors, dietary influences, and host-microbe interactions, and has caught the attention of researchers worldwide; considerable efforts now being directed towards understanding the role of dysbiosis in the pathogenesis of IBD. However, there remain several gaps in our understanding of this complex condition.

Researchers from the Peking Union Medical College, China and the Chinese Academy of Medical Sciences have delved deeper into understanding multi-dimensional dysbiosis and technologies that can aid the diagnosis and treatment of IBD. “Over the past decade, our knowledge on the microenvironment has boomed, with the development of next-generation sequencing, enabling a closer look at the dynamics of microbial interactions and functional alternations,” says Professor Jing-Nan Li, corresponding author of their review article, published in the Chinese Medical Journal on 5th April 2020.

The researchers first discuss the differences in gut microbiota in patients with IBD and healthy individuals, and how these changes can trigger imbalances in important metabolites such as short chain fatty-acids, required for normal physiological processes. Next, they describe the “mycobiome” or fungal microbiota, that has been relatively less explored, and their interplay with bacterial populations. They further shed light on the interaction of intestinal fungi with host immune responses and metabolic pathways, and how these interactions help maintain gut “homeostasis” (balance).

The researchers also elaborate on advanced technologies that enable a holistic understanding of complex diseases like IBD. A “multi-omics” (multiple sequencing) approach integrates changes at the transcriptional and translational level (RNA and proteins) and metabolic pathways, in response to dysbiosis. Such integrated approaches combining genetic, metabolic and environmental factors can uncover novel biomarkers to predict the course of the disease and treatment outcomes. Yet, these techniques have not been harnessed fully, due to their elaborate data interpretation and analysis, underscoring the scope for optimization of sequencing technologies and data processing for maximum output.

Finally, the review highlights therapeutic strategies such as “fetal microbiota transplantation” and “supplementary probiotics” that can help replenish gut microbiota and restore balance. Additional studies in this direction can help devise effective treatment regimens for IBD and associated disorders.

“Future efforts towards IBD associated intestinal micro-environment shifts should focus on the standardization of environmental confounding factors, like dietary and oral medications,” concludes Prof. Li.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine